Wed, February 13, 2013
Tue, February 12, 2013
Mon, February 11, 2013
Sun, February 10, 2013
Fri, February 8, 2013
Thu, February 7, 2013
Wed, February 6, 2013
Tue, February 5, 2013
Mon, February 4, 2013
Sun, February 3, 2013
Sat, February 2, 2013
Fri, February 1, 2013
Thu, January 31, 2013
Wed, January 30, 2013
Tue, January 29, 2013
[ Tue, Jan 29th 2013 ] - Market Wire
AtheroNova Launches New Website
Mon, January 28, 2013
Sun, January 27, 2013
Sat, January 26, 2013
Fri, January 25, 2013
Thu, January 24, 2013

Pegasus Invited to Present at PDA Fungal Contamination Control Conferences


//health-fitness.news-articles.net/content/2013/ .. da-fungal-contamination-control-conferences.html
Published in Health and Fitness on Tuesday, February 5th 2013 at 8:45 GMT by Market Wire   Print publication without navigation


February 05, 2013 11:33 ET

Pegasus Invited to Present at PDA Fungal Contamination Control Conferences

PALM BEACH GARDENS, FL--(Marketwire - Feb 5, 2013) - Pegasus Pharmaceuticals (PINKSHEETS: [ PGUZ ]) has introduced to the pharmaceutical industry an innovative product that effectively controls fungi/mold cells and prevents long-term spore growth at PDA (Parenteral Drug Association) conferences in Chicago and Phoenix. The company also presented at a contamination control conference in Dublin, Ireland in October 2012 attended by many major pharmaceutical companies. The product generated much interest and company visits. Pegasus is working with industry experts to customize product applications for pharmaceutical needs. Pegasus's product is based on a new biological approach, which controls mold spores and prevents their growth. The formulation utilizes non-toxic, natural compounds with green chemistry and pharmaceutical/food grade ingredients. The active ingredients are non-hazardous to humans and are very specific to fungi. The combination of environmentally friendly natural ingredients controls the spore life cycle and has long-term antimycotic effects. This feature has a long lasting prophylactic effect on fungi growth.

The company is completing product development studies and tests prior to regulatory submission.

For more information, visit the Company's website: [ www.pegasusbiosciences.com ] or contact Daniel Kesonen, Chairman and CEO, Pegasus Pharmaceuticals, Inc. by telephone at 561-626-9901 or by email at [ dkesonen@gmail.com ]



Publication Contributing Sources